Do not neglect myopia
The percentage of children with vision less than 1.0 has reached a record high. The shocking news was reported in Japan in the fall of 2023.
According to a survey conducted by the Ministry of Education, Culture, Sports, Science and Technology, the percentage of children with less than 1.0 naked eye vision was about 38% for elementary school students, 61% for junior high school students, and 71% for high school students.
In fact, the WHO has sounded the alarm by predicting that about half of the world's population will be nearsighted by 2050. Now there is a growing awareness around the world that myopia is a "disease" that needs to be treated.
If you think you do not need to worry about myopia because you can just wear glasses, think again. Myopia has been shown to increase the risk of developing diseases that can lead to blindness in the future. On the other hand, it has become clear that myopia can be prevented by simply looking at the distance outside for a few hours each day.
While there are many eye drops and eye supplements sold in Japan, there are also dubious stories circulating about "methods to restore eyesight. Now more than ever, there is a need to educate people about their eyes.
In this book, the author, an ophthalmologist and researcher, provides "useful" and "world standard" information about the eyes.
Overview
Table of Contents
Chapter 2: Smartphone Risk for Children! --Japanese people do not know enough about their eyes!
Chapter 3: Myopia is now being "treated" -- "Playing outside" is effective!
Chapter 4: Surprisingly Unknown "Eye Diseases" - Nearsightedness increases the risk of developing eye diseases
Chapter 5: What is common sense in Japan is nonsense in the rest of the world? —From eye drops and supplements to eye muscle relaxants
Chapter 6: What are really "good" choices for the eyes? Are Contacts and ICL Safe?
Author Profile
Born in 1966. Graduated from the Keio University School of Medicine. He was a visiting professor at Keio University School of Medicine, a research representative for NASA HRP in the U.S., and a board member of NBR, a U.S. think tank.
After working at Toranomon Hospital, he became an assistant professor at the University of Washington in Seattle, U.S.A. In 2002, he founded Acucela, a drug discovery company. In 2016, he established Kubota Pharmaceutical Holdings, Inc. and moved its headquarters to Japan. Acucela became a wholly owned subsidiary and was re-listed on the TSE Mothers. In addition to research and development for Stargardt's disease and diabetic retinopathy based on its proprietary visual cycle modulation technology, the company is also working with NASA in the field of home and telemedicine to develop cloud-based home medical monitoring devices such as ultra-compact OCT and wearable myopia devices. In the field of home and telemedicine, the Company is collaborating with NASA on the research and development of cloud-based home medical monitoring devices, such as ultra-compact OCT and wearable myopia devices.
